Drug Trial Radar · NCT04128696
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
315
Actual
Start
Nov 21, 2019
Primary completion
Apr 27, 2021
Study completion Jun 20, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) \>=1 R/M HNSCC.
Conditions
- Neoplasms, Head and Neck
Interventions
feladilimabDrug
feladilimab is available as an intravenous infusion.
PembrolizumabDrug
Pembrolizumab is available as an intravenous infusion.
PlaceboDrug
Placebo is available as an intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in the Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 PopulationTime frame: Up to approximately 16 months
- OS in the PD-L1 Expression High (CPS ≥20) PopulationTime frame: Up to approximately 16 months
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 PopulationTime frame: Up to approximately 16 months
Locations
163 sites in 26 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Chattanooga, Tennessee
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
San Juan, Argentina
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Darlinghurst, Australia
GSK Investigational Site
Blacktown, New South Wales, Australia
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vitória, Espírito Santo, Brazil
GSK Investigational Site
Florianópolis, Santa Catarina, Brazil
GSK Investigational Site
Barretos, São Paulo, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, Brazil
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Rimouski, Quebec, Canada
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.